Trials / Completed
CompletedNCT04594252
Copper Balance in Healthy Participants Administered ALXN1840
A Phase 1, Open-label Study to Assess Copper Balance in Healthy Participants Following Administration of ALXN1840
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The study will assess the change from baseline in mean daily copper balance in healthy participants with repeat-dose administrations of ALXN1840 over 2 weeks.
Detailed description
This study will also characterize the steady state absorption, distribution, metabolism, and excretion (mass balance) of total molybdenum, which is a surrogate measure of ALXN1840 disposition. Safety will be monitored throughout the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALXN1840 | Administered orally as tablets. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2020-11-18
- Completion
- 2020-11-18
- First posted
- 2020-10-20
- Last updated
- 2024-08-19
- Results posted
- 2024-08-19
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04594252. Inclusion in this directory is not an endorsement.